41 reports

  • 15.2 PERSONALIZED MEDICINE TO SPUR USE OF LIQUID BIOPSY TESTS IN
  • 3.3 GLOBAL LIQUID BIOPSY MARKET SHARE & FORECAST - BY APPLICATION

Other Fluids Sample ##.

  • Biopsy
  • World
  • Forecast
  • Market Size
  • MDxHealth SA
  • 1.2 ISSUES ADDRESSED BY LIQUID BIOPSY & BIOMARKERS DETECTED
  • LIQUID BIOPSY: DETECTION OF CANCER BIOMARKERS

(UK) COMPANY ## COMPANY ## Trovagene, Inc.

  • Biopsy
  • United States
  • Market Size
  • Biocept, Inc.
  • Biodesix Inc.
  • 11.15.4 KEY DEVELOPMENTS
  • Date

Tel: + ##-##-##-## Fax: + ##-##-##-## Website: www. illumina. com ##. ##. ## OVERVIEW Illumina is one of the world leaders in sequencing and array based solutions for genetic analysis.

  • Biopsy
  • World
  • Market Size
  • Biocept, Inc.
  • Guardant Health, Inc.

Chapter ##: Introduction Study Goals and Objectives BCC Research’s goal for this study is to provide an in-depth update study of the liquid biopsy diagnostics industry, an emerging industry with high market potential.

  • Biopsy
  • Diagnostics
  • World
  • Forecast
  • Market Size
  • OTHER PROMINENT VENDORS

It is a new entrant in the market, which develops liquid biopsy products based on genetic technology.

  • Biopsy
  • Biocept, Inc.
  • Exosome Diagnostics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • QIAGEN N.V.
  • CTDNA PLATFORMS FOR DETECTION OF EGFR MUTATIONS
  • LIQUID BIOPSY: INSIGHTS

Fig ## PARADIGM SHIFT: RX TO CDX Fig ## ## ## ## ## ## ## ADVANCEMENTINTHERAPYAREAS ANALYSIS Sense and Response Predict and Act?

  • Biopsy
  • North America
  • United States
  • World
  • Market Size

Moreover, unlike tissue biopsies, which are obtained from only one tumor region, a liquid biopsy can better reflect the genetic profile of all tumor sub-clones present in the patient.

  • Biopsy
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • MDxHealth SA
  • OPKO Health, Inc.
  • Advantages of Liquid Biopsy in Screening Market
  • ii. Guide for Executives, Marketing, Sales and Business Development Staff

“Blood Tests replace Surgical Biopsies. Single screening test for all cancers announced .....” The Diagnostic, Monitoring and Screening Test opportunities are explored. A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. The technology creates new markets for cancer...

  • Biopsy
  • United States
  • Market Size
  • Illumina, Inc.
  • Trovagene, Inc.
  • Advantages of Liquid Biopsy in Screening Market
  • ii. Guide for Executives, Marketing, Sales and Business Development Staff

Circulating Tumor Cell, Cell Free DNA and Exosome/Microvesicle Cancer Diagnostics by Lung, Breast, Colorectal, Prostate and Other. 2017-2020 Including Screening Market Potential Size with Executive and Consultant Guides “Blood Tests replace Surgical Biopsies. Single screening test for all cancers announced .....” The...

  • Biopsy
  • United States
  • Market Size
  • Illumina, Inc.
  • Trovagene, Inc.
  • NEOGENOMICS
  • SELECTED LIQUID BIOPSY TESTS BASED ON EXTRACELLULAR VESICLES/OTHER ANALYTES, 2017

MOREOVER, THE DETECTION OF MUTATIONS ON CTDNA, ESPECIALLY THE RARE ONES, BECOMES HIGHLY DIFFICULT, SINCE GENETIC MUTATIONS OCCUR INFREQUENTLY AND APPEAR IRREGULARLY THROUGHOUT THE GENOME.

  • Biopsy
  • World
  • Epigenomics AG
  • QIAGEN N.V.
  • Roche Group
  • MARKET SIZE AND FORECAST

You can request one free hour of our analyst’s time when you purchase this market report.

  • Biopsy
  • Diagnostics
  • World
  • Market Size
  • Diagnostic laboratories - Market size and forecast 2017-2022

You can easily book an appointment with one online.

  • Biopsy
  • United States
  • Agilent Technologies, Inc.
  • Illumina, Inc.
  • Thermo Fisher Scientific, Inc.
  • ISET TEST
  • PREDISEQ-LUNG

GENETIC TECHNOLOGIES ##.

  • Biopsy
  • North America
  • United States
  • Market Size
  • Biocept, Inc.

Excisional Biopsy ##.

  • Biopsy
  • United States
  • B. Braun Melsungen AG
  • Becton Property Group
  • Boston Scientific Corporation

Through the detection of different biomarkers, the diagnosis of cardiovascular diseases, infections, immunological and genetic disorders is certainly possible and opens new hopes for the patients.

  • Biopsy
  • Diagnostics
  • World
  • Market Size

Cancer, a global pandemic, is one of the leading causes of deaths worldwide.

  • Biopsy
  • Diagnostics
  • World
  • Market Size

Global Liquid Biopsy Figure ##.

  • Biopsy
  • Diagnostics
  • World

Strategic Initiatives List of Table Table ##.

  • Biopsy
  • Diagnostics
  • United States
  • Market Size
  • 2.2 United States - Liquid Biopsy Screening Potential Market
  • United States - Liquid Biopsy Potential Market (Million US$), 2015 - 2020

Liquid Biopsy Market - Major Deals Analysis ##.

  • Biopsy
  • Diagnostics
  • United States
  • Forecast
  • Biocept, Inc.
  • LIQUID BIOPSY EPIGENETIC ASSAY - ORAL CANCER - PRODUCT STATUS

Summary MDxHealth SA (MDxHealth) develops and commercializes advanced epigenetic and other molecular tests for cancer assessment and the personalized treatment of patients.The company’s products portfolio includes ConfirmMDx, which detects absence or presence of prostate cancer; SelectMDx for prostate cancer; and AssureMDx...

  • Biopsy
  • Prostate Cancer
  • United States
  • Company
  • MDxHealth SA
  • Mar 20, 2018: Precipio Integrates Cost Reducing and Fast Turnaround "High Resolution Melt" into Liquid Biopsy Platform
  • Apr 03, 2018: Important JAMA Article Underscores Superiority of Precipio's Liquid Biopsy Core Technology

The series A-## preferred shares are convertible into shares of common stock at an initial rate of ##-for-##, with the conversion rate subject to further adjustment.

  • Biopsy
  • Genome Sequencing
  • Medical Device
  • United States
  • Precipio, Inc.
  • Mar 20, 2018: Precipio Integrates Cost Reducing and Fast Turnaround "High Resolution Melt" into Liquid Biopsy Platform
  • Sep 29, 2016: Transgenomic Adds New Distributors in China and India for its ICEme Kits that Enable Liquid Biopsy Cancer Testing on Existing Platforms

The series A-## preferred shares are convertible into shares of common stock at an initial rate of ##-for-##, with the conversion rate subject to further adjustment.

  • Biopsy
  • Genome Sequencing
  • Medical Device
  • United States
  • Precipio, Inc.
  • DEC 05, 2017: FIRST U.S. PATENT ISSUED FOR BIOCEPT'S TARGET SELECTOR ONCOGENE MUTATION ENRICHMENT AND DETECTION LIQUID BIOPSY CTDNA PLATFORM
  • DEC 05, 2017: FIRST U.S. PATENT ISSUED FOR BIOCEPT'S TARGET SELECTOR ONCOGENE MUTATION ENRICHMENT AND DETECTION LIQUID BIOPSY CTDNA PLATFORM

Biocept will develop and commercialize one or more tests.

  • Biopsy
  • Lung Cancer
  • Medical Device
  • United States
  • Biocept, Inc.

The combined purchase price for one share of common stock (or one pre-funded warrant to purchase common stock in lieu thereof) and each warrant will be priced at USD##. ##.

  • Biopsy
  • Pharmaceutical
  • United States
  • Company
  • Biocept, Inc.
  • LIQUID BIOPSY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND
  • THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2016)

(US), raised funds worth USD ## billion, with Tencent (China) being one of its investors.

  • Biopsy
  • North America
  • United States
  • Forecast
  • Market Size

On August ##, 2012, Cynvenio raised additional $##. ##m in second tranche of series B round, bringing the proceeds to $##m.

  • Biopsy
  • Biosystem
  • Medical Device
  • United States
  • Cynvenio Biosystems, Inc.
  • Jun 03, 2017: Cure-One Announces Partnership with Guardant Health
  • Dec 14, 2017: Liquid Biopsy Results Differed Substantially Between Two Providers

Just ## of the ## patients in the study had at least one genetic mutation reported within the overlapping genetic sequences covered by both companies.

  • Biopsy
  • Cancer
  • United States
  • Company
  • Guardant Health, Inc.

The results were published in PLoS ONE and build on previous development work on the InVision platform also recently published in PLoS ONE.

  • Biopsy
  • Cancer
  • Clinical Trial
  • Lung Cancer
  • Inivata Limited